Rosemarie Delaney

Dr. Rosemarie Delaney is an accomplished professional with over 25 years of experience in the pharmaceutical industry, serving in senior roles across Pharmaceutical, Vaccine, and Medical Device corporations at UK, European, and Global Director levels. Currently, she is the Vice President and Head of Market Access.

Rosemarie is a seasoned Market Access expert with extensive experience in a wide range of therapeutic areas. Her expertise includes Global Market Access Strategy, Pricing and Reimbursement (P&R), and Value Proposition Development. Her leadership and operational insights have significantly contributed to various organisations.

From 2020 to 2024, Rosemarie served as the Senior Director for Government Affairs and Market Access (GAMA) at Indivior UK Ltd, focusing on treatments for Opioid Use Disorder (OUD) across Europe and Canada. Prior to this, between 2015 and 2020, she was the Director of RD Consulting Ltd, working as a contractor and consultant in Market Access. During this period, she contributed to projects for notable organisations including Norgine, where she held roles such as Interim Global Market Access and Government Affairs Manager and Interim Global Market Access Director. Other roles included Executive Advisor for Lightning Health, Interim Associate Director for Global Market Access at Eisai, and Interim Pricing, Insights, and Market Access Strategist at Pfizer.

Between 2014 and 2013, she was the Disease Area Market Access Lead (Director) for Cardiovascular Europe at Bristol-Myers Squibb, focusing on Atrial Fibrillation. Prior to this, she spent five years (2008-2013) with SANOFI PASTEUR MSD as the Vaccine Market Access Lead in the UK. Rosemarie also held various marketing and leadership roles in SERVIER LABORATORIES LTD from 2000 to 2008, contributing to the Cardiovascular and Diabetes portfolios. Her earlier career includes positions as a Scientific Marketing Specialist at PALL MEDICAL and as a Lecturer in Clinical Pharmacology at the Royal College of Surgeons in Ireland.

Rosemarie’s expertise spans Market Access strategy and execution, Pricing and Reimbursement, Health Technology Appraisal, Payer Insights, and Value Proposition Development. She has extensive therapeutic experience in areas such as Addiction and Opioid Use Disorder, Cardiovascular conditions (e.g., Atrial Fibrillation, Heart Failure, Hypertension, and Iron Deficiency Anaemia), Diabetes, and Vaccines for oncology and infectious diseases (e.g., Gardasil for Cervical Cancer, Zostavax for Shingles). Her oncology experience also includes cervical cancer vaccines, colonoscopy devices, and treatments for hepatocellular carcinoma.

Throughout her career, she has worked on Market Access, Pricing, and Reimbursement for a variety of products, including new formulations of existing drugs such as injectable Buprenorphine, blockbuster cardiovascular compounds like Eliquis, and novel vaccines and medical devices. Her functional expertise lies in Market Access Strategy, Pricing, and Reimbursement, with a proven track record of delivering results.